Cochrane Abstracts
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Target of Rapamycin Inhibitors (TOR‐I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I.
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I. Accessed February 1, 2025.
Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I
Target of Rapamycin Inhibitors (TOR‐I; Sirolimus and Everolimus) for Primary Immunosuppression in Kidney Transplant Recipients [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 February 01]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
ID - 439776
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439776/all/Target_of_rapamycin_inhibitors__TOR‐I
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
